DMAC
vs
S&P 500
DMAC
S&P 500
Over the past 12 months, DMAC has outperformed S&P 500, delivering a return of +22% compared to the S&P 500's +17% growth.
Stocks Performance
DMAC vs S&P 500
Performance Gap
DMAC vs S&P 500
Performance By Year
DMAC vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
DiaMedica Therapeutics Inc
Glance View
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. The company is headquartered in Minneapolis, Minnesota and currently employs 14 full-time employees. The company went IPO on 2008-01-04. The firm is focused on developing treatments for neurological and kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The firm's lead product DM199 mimics the behavior of naturally occurring human kallikrein-1 (KLK1) proteins to preserve and restore circulation to stroke-damaged tissue and improve overall kidney function. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. DM199 therapy has the potential to improve circulation and overall function of critical systems, as well as reduce inflammation and oxidative stress. The firm also has other product pipelines for IgA Nephropathy and African Americans with CKD.
